| Assessment Status | Assessment process complete |
| HTA ID | - |
| Drug | Sunitinib |
| Brand | Sutent® |
| Indication | As second-line treatment of patients with gastro-intestinal stromal tumours (GIST); As second line treatment for patients with metastatic renal cell carcinoma (mRCC) |
| Assessment Process |